Email Facebook Twitter

RNS EXCLUSIVE: Cabot praise 3D seismic mapping after successful winter programme

ShareCast News

Goldman Sachs upgrades Mediclinic to 'neutral' after underperformance

Thu, 5th Oct 2017 08:22

(ShareCast News) - Goldman Sachs has upgraded Mediclinic to 'neutral' from 'sell' following underperformance.

The bank noted that since being added to the 'sell' list on 1 June 2017, the stock is down 17% versus the MSCI EEMEA down 0.7%. It argued that Mediclinic's share price now fairly reflects the negative read-across for its South African business for the LHC/NTC trading updates as well as integration post inorganic expansion of its UAE business.

Goldman, which cut its price target on the stock to 670p from 700p, said the environment remains challenging across all three of Mediclinic's segments. In South Africa, it expects a weak labour market to continue pressuring the company's patient volumes, while any material improvement in EBITDA margins in FY18-20E appears unlikely due to subdued occupancy rates.

Meanwhile, in Switzerland, it expects growth to remain in low single digits, with no capacity additions and already high occupancy rates, and EBITDA margins in FY18/19 to decline on revisions to outpatient tariffs.

In the UAE, Goldman has yet to see the company executing on Al Noor integration issues and demonstrating an improvement in the company's legacy Dubai business. It estimates only around5% growth in the legacy business in FY18E, broadly in line with FY17.

"Nevertheless, given MDC's circa 12% share price drop over the last three months, we believe that the risk/reward profile is now balanced," GS said.

At 0955 BST, the shares were up 1.2% to 661.50p.

Back to ShareCast News

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.